文献速递临床试验与 GCP流行病学与生物统计

早期乳腺癌剂量密集化疗的患者水平荟萃分析

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
PubMed 文献 · Lancet · 2019-02-08

该研究对26项随机试验中37 298例早期乳腺癌患者进行个体患者水平荟萃分析,比较剂量密集方案与标准方案化疗。

要点

  • 2周方案与序贯方案均显示复发风险降低,且ER阳性与阴性亚组获益一致。
  • 剂量密集方案未增加非复发死亡,总生存获益。

核心结论

  • 通过缩短化疗间隔或序贯给予单个药物可中度降低早期乳腺癌10年复发和死亡风险,且不增加其他原因死亡。

研究设计与样本

  • 个体患者水平荟萃分析,纳入26项随机试验的37 298例早期乳腺癌患者(占相关试验随机总数的93%)。
  • 比较2周方案与标准3周方案,以及蒽环类和紫杉类序贯与同时给药的试验。
  • 主要结局为复发和乳腺癌死亡,采用分层log-rank分析计算率比(RR)。

临床怎么用

  • 对于适合辅助化疗的早期乳腺癌患者,可考虑采用缩短间隔或序贯给药的剂量密集方案以改善长期结局。

局限性

  • 仅纳入提供个体数据的26项试验(占相关试验的93%),未提供数据的试验可能带来选择偏倚。
  • 多数患者为70岁以下且淋巴结阳性,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. METHODS: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios (RRs). FINDINGS: Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more dose-intense arm. Combining data from all 26 trials, fewer breast cancer recurrences were seen with dose-intense than with standard-schedule chemotherapy (10-year recurrence risk 28·0% vs 31·4%; RR 0·86, 95% CI 0·82-0·89; p<0·0001). 10-year breast cancer mortality was similarly reduced (18·9% vs 21·3%; RR 0·87, 95% CI 0·83-0·92; p<0·0001), as was all-cause mortality (22·1% vs 24·8%; RR 0·87, 95% CI 0·83-0·91; p<0·0001). Death without recurrence was, if anything, lower with dose-intense than with standard-schedule chemotherapy (10-year risk 4·1% vs 4·6%; RR 0·88, 95% CI 0·78-0·99; p=0·034). Recurrence reductions were similar in the seven trials (n=10 004) that compared 2-weekly chemotherapy with the same chemotherapy given 3-weekly (10-year risk 24·0% vs 28·3%; RR 0·83, 95% CI 0·76-0·91; p<0·0001), in the six trials (n=11 028) of sequential versus concurrent anthracycline plus taxane chemotherapy (28·1% vs 31·3%; RR 0·87, 95% CI 0·80-0·94; p=0·0006), and in the six trials (n=6532) testing both shorter intervals and sequential administration (30·4% vs 35·0%; RR 0·82, 95% CI 0·74-0·90; p<0·0001). The proportional reductions in recurrence with dose-intense chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor (ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics. INTERPRETATION: Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes. FUNDING: Cancer Research UK, Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019. PMID: 30739743. doi:10.1016/S0140-6736(18)33137-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。